Krystal Biotech (KRYS) Shows Promising Results in KB301 Study

By Bobby Samwell • Thursday, August 29 07:56 • Permanent Link

Jeune Aesthetics, Inc. recently reported positive interim safety and efficacy results for KB301 in their phase 1 study, Pearl-1. This study evaluated the investigational aesthetic treatment's ability to deliver the Col3a1 transgene and increase type III collagen levels in the skin, specifically targeting lateral canthal lines and dynamic wrinkles of the décolleté.

For the décolleté region, the study found that 94% of subjects experienced at least a one-point improvement in wrinkles two months after treatment, with 28% showing a two-point improvement. Additionally, 94% of subjects reported improved satisfaction with their wrinkles’ appearance two months after treatment. Furthermore, improvements were seen in crepiness, hydration, and radiance, with at least 89% of subjects showing improvements in these skin attributes two months after treatment.

In the lateral canthal region, the study revealed that 75% of subjects experienced at least a one-point improvement in wrinkles two months after treatment, with 50% showing a two-point improvement. Similarly, 67% of subjects reported improved satisfaction with their wrinkles’ appearance two months after treatment. Moreover, improvements were reported in crepiness, hydration, and radiance, with at least 75% of subjects showing improvements in these skin attributes two months after treatment.

The safety profile of KB301 was consistent with prior clinical experience, with primarily mild-to-moderate and transient adverse events. No drug-related serious adverse events were reported.

Following these promising results, Jeune Aesthetics plans to initiate a phase 2 study for the treatment of dynamic wrinkles of the décolleté.

The company is set to host a conference call and webcast to discuss the interim results and provide insight into their clinical development program, pipeline product candidates, and strategic vision.

Following these announcements, the company's shares moved 2.9%, and are now trading at a price of $203.91. For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.